1185 related articles for article (PubMed ID: 8819128)
21. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.
Schmollinger JC; Vonderheide RH; Hoar KM; Maecker B; Schultze JL; Hodi FS; Soiffer RJ; Jung K; Kuroda MJ; Letvin NL; Greenfield EA; Mihm M; Kutok JL; Dranoff G
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3398-403. PubMed ID: 12626761
[TBL] [Abstract][Full Text] [Related]
22. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
Wei XX; Chan S; Kwek S; Lewis J; Dao V; Zhang L; Cooperberg MR; Ryan CJ; Lin AM; Friedlander TW; Rini B; Kane C; Simko JP; Carroll PR; Small EJ; Fong L
Cancer Immunol Res; 2016 Nov; 4(11):948-958. PubMed ID: 27688020
[TBL] [Abstract][Full Text] [Related]
23. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
24. Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model.
Kalaaji AN; Lu J; Markovic SN; Celis E; Pittelkow MR
Cytokine; 2010 Mar; 49(3):287-93. PubMed ID: 20060741
[TBL] [Abstract][Full Text] [Related]
25. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.
Håkansson A; Gustafsson B; Krysander L; Håkansson L
Br J Cancer; 1996 Sep; 74(5):670-6. PubMed ID: 8845294
[TBL] [Abstract][Full Text] [Related]
26. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
27. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
[TBL] [Abstract][Full Text] [Related]
30. Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.
Aris M; Bravo AI; Pampena MB; Blanco PA; Carri I; Koile D; Yankilevich P; Levy EM; Barrio MM; Mordoh J
Front Immunol; 2018; 9():955. PubMed ID: 29774030
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
32. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
Harris RC; Chianese-Bullock KA; Petroni GR; Schaefer JT; Brill LB; Molhoek KR; Deacon DH; Patterson JW; Slingluff CL
J Immunother; 2012 Jan; 35(1):78-88. PubMed ID: 22130163
[TBL] [Abstract][Full Text] [Related]
33. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Atzpodien J; Fluck M; Reitz M
Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
[TBL] [Abstract][Full Text] [Related]
34. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
35. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat.
Jean WC; Spellman SR; Wallenfriedman MA; Flores CT; Kurtz BP; Hall WA; Low WC
J Neurooncol; 2004 Jan; 66(1-2):39-49. PubMed ID: 15015768
[TBL] [Abstract][Full Text] [Related]
36. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte-macrophage colony-stimulating factor drives monocytes to CD14low CD83+ DCSIGN- interleukin-10-producing myeloid cells with differential effects on T-cell subsets.
Ganguly D; Paul K; Bagchi J; Rakshit S; Mandal L; Bandyopadhyay G; Bandyopadhyay S
Immunology; 2007 Aug; 121(4):499-507. PubMed ID: 17433076
[TBL] [Abstract][Full Text] [Related]
38. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R
Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
Djalilian HR; Caicedo E; Lessan K; Grami V; Le CT; Spellman SR; Pambuccian S; Hall WA; Low WC; Ondrey FG
Cancer Immunol Immunother; 2007 Aug; 56(8):1207-14. PubMed ID: 17219150
[TBL] [Abstract][Full Text] [Related]
40. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
